Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
复制标题
血浆中的五种 microRNA 作为筛查早期非小细胞肺癌的新型生物标志物
DOI：
10.1186/s12931-014-0149-3
复制
发表时间：
2014-11-25
影响因子：
5.8
通讯作者：
Hu H
中科院分区：
文献类型：
--
作者：
Geng Q;Fan T;Zhang B;Wang W;Xu Y;Hu H
为了寻找新的非侵袭性生物标志物用于早期非小细胞肺癌（NSCLC）的筛查，我们研究了5种microRNA（miR-20 a、miR-145、miR-21、miR-223和miR-221）作为早期NSCLC潜在生物标志物的预测能力。在训练集中，包括25名早期NSCLC患者和25名匹配的健康对照，以通过实时RT-PCR评估早期NSCLC患者和健康对照之间的miRNA表达谱。我们发现，与健康组相比，NSCLC患者中的5种miRNAs（miR-20 a、miR-223、miR-21、miR-221和miR-145）水平显著失调，因此被选择为验证集。因此，基于126名早期NSCLC患者、42名NCPD患者和60名健康对照，进一步进行验证实验以研究这五种miRNA的潜在预测能力。生成五种miRNA的受试者工作特征（ROC）曲线。ROC曲线分析表明，这5种血浆miRNAs可能是NSCLC有希望的生物标志物，其AUC值相对较高，分别为：miR-20 a，0.89，95%CI为[0.85-0.93]; miR-223，0.94，95%CI为[0.91-0.96]; miR-21，0.77，95%CI为[0.71-0.83]; miR-155，0.92，95% CI为[0.89-0.96]; miR-145，0.77，95% CI为[0.71-0.83]。分层分析显示，血浆miR-20 a、miR-223、miR-21和miR-145对吸烟者的预测价值优于非吸烟者，而miR-155可能更适合于非吸烟者。此外，所有这五种miRNAs都可以区分NSCLC和对照组，在晚期和鳞状细胞癌亚组中具有更高的准确性。总之，我们的研究提示5种血浆miRNAs（miR-20 a、miR-145、miR-21、miR-223和miR-221）可作为NSCLC早期筛查的有希望的生物标志物。然而，进一步的验证和优化改进，需要进行更大的样本，以确认我们的结果。
In order to find novel noninvasive biomarkers with high accuracy for the screening of early-stage non-small cell lung cancer (NSCLC), we investigate the predictive power of 5 microRNAs (miR-20a, miR-145, miR-21, miR223 and miR-221) as potential biomarkers in early-stage NSCLC. In training set, 25 early-stage NSCLC patients and 25 matched healthy controls are included to assess the miRNA expression profile between early-stage NSCLC patients and healthy controls by real-time RT-PCR. We found that five of these miRNAs (miR-20a, miR-223, miR-21, miR-221 and miR-145) levels in NSCLC patients were significantly dysregulated compared with the healthy groups and thus were selected to validation set. Therefore, a validation experiment was further performed to investigate the potential predictive power of these five miRNAs based on 126 early-stage NSCLC patients, 42 NCPD patients and 60 healthy controls. The receiver operating characteristic (ROC) curves were generated for the five miRNAs. ROC curve analyses suggested that these five plasma miRNAs could be promising biomarkers for NSCLC, with relatively high AUC values as follows: miR-20a, 0.89 with 95% CI of [0.85-0.93]; miR-223, 0.94 with 95% CI of [0.91-0.96]; miR-21, 0.77 with 95% CI of [0.71-0.83]; miR-155, 0.92 with 95% CI of [0.89-0.96]; miR-145, 0.77 with 95% CI of [0.71-0.83]. Stratified analyses indicated that plasma miR-20a, miR-223, miR-21 and miR-145 showed better predictive value in smokers than in non-smokers, while miR-155 might be more suitable for non-smokers. In addition, all of these five miRNAs could differentiate NSCLC from controls with a higher accuracy in advanced stage and squamous carcinoma subgroups. In conclusion, our study suggested that five plasma miRNAs (miR-20a, miR-145, miR-21, miR-223 and miR-221) can be used as promising biomarkers in early screening of NSCLC. Nevertheless, further validation and optimizing improvement should be performed on larger sample to confirm our results.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
64.8
作者：
Lu, J;Getz, G;Golub, TR
通讯作者：
Golub, TR
影响因子：
6.1
作者：
Bi Chong Lei;Chng Wee Joo
通讯作者：
Chng Wee Joo
影响因子：
64.8
作者：
O'Donnell, KA;Wentzel, EA;Mendell, JT
通讯作者：
Mendell, JT
影响因子：
6.5
作者：
Lawrie, Charles H.;Gal, Shira;Harris, Adrian L.
通讯作者：
Harris, Adrian L.